Skip to main content
AmigoFish

Derms on Drugs

Scholars in MedicineAudio

Format:
Podcast
New episodes:
Weekly
Typical length:
about 30 minutes
Latest episode:
Not rated yet

About this show

Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.

It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.

Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.

Covers: dermatology, medical education, clinical trials, hidradenitis suppurativa, atopic dermatitis, urticaria, hair loss, medical AI

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

Derms on Drugs is a podcast where three dermatologists discuss and debate current topics in skin medicine, aimed at clinicians. Recent episodes cover pyoderma gangrenosum, remibrutinib for chronic spontaneous urticaria, high-dose vitamin D, and AI-issued acne prescriptions in Utah.

Report a problem with this summary

Cosmos

Similar by topic and creator

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • Creams, Screams, and Measles

    · 47 min

    Pediatric dermatology legend Dr. Sheila Fallon Friedlander joins the Derms to sort through the new topical “Goldilocks” problem, take the sting out of Dupixent injections, and make the case for treating molluscum sooner. Plus, how to recognize measles—and why its most frightening complication may not appear for years.

    Not rated yet
  • Can We Stop Referring CSU?

    · 26 min

    The CSU rulebook is getting a rewrite, and the Derms on Drugs crew has thoughts. Dr. Jason Hawkes joins the conversation to talk new guidelines, new therapies, and why it may be time to stop sending these patients somewhere else.

    Not rated yet
  • The Gray Zone Strikes Again

    · 46 min

    This week, the DoD tackle studies that leave plenty of room for debate—from skin cancer treatment costs and melanoma risk to HS, alopecia areata, and the real-world decisions that don't always come with straightforward answers.

    Not rated yet
  • Making Nails Sexy Again

    · 48 min

    The DOD tackle longitudinal melanonychia, retronychia, nail biopsies, and other everyday nail problems—with enough practical pearls to make you rethink your next nail patient.

    Not rated yet
  • Clinical Controversies: Screening, Patch Testing & Physician Burnout

    · 46 min

    One paper questions melanoma screening. Another challenges patch testing. By the end, the conversation has wandered into studies on physician burnout and more, sparking exactly the kind of debate you'd expect from DoD.

    Not rated yet
  • What If the Biopsy Picked the Biologic?

    · 45 min

    Dermatologist William Damsky, MD, joins the DoD crew to explore immune biomarkers, treatment prediction, and whether precision dermatology is finally ready for prime time.

    Not rated yet
  • Don't Blame the Canary

    · 56 min

    Burnout isn't just about long hours. From moral distress to prior authorizations and system barriers, this week's conversation with Dr. Lisa Swanson explores what's really wearing physicians down—and why resilience alone won't fix it.

    Not rated yet
  • Bad Ideas, Good Outcomes, and Thin Melanomas

    · 54 min

    Thin melanomas that behave badly, a surprisingly intriguing role for oxybutynin in HS, and a reminder that some of dermatology’s most trusted assumptions deserve a second look. This week’s 6-pack is all about the exceptions that force us to rethink the rules.

    Not rated yet
  • When Psoriasis Pretends to Be Eczema (And Other Problems)

    · 44 min

    The diagnoses get messy, the treatment decisions get interesting, and the DoD crew has opinions. From a major scabies study to a practical overlap-disease pearl, this week's episode is full of reminders that dermatology is rarely as straightforward as it seems.

    Not rated yet
  • French Bathhouses, Vitiligo Hacks & the Myth of the ‘Cure’

    · 41 min

    An emerging infection out of France, a surprisingly clever vitiligo combo, and a spirited debate about whether medicine has ever actually cured anything. Just another normal week on Derms on Drugs.

    Not rated yet
  • Rewind: Melanoma Meltdowns, Biosimilar Betrayals, and the Eczema Enigma Exposed!

    · 1 hr 1 min

    Melanoma, Anxiety, and Depression Links; Biosimilars vs Humira; Air Pollution and Atopic Dermatitis – Have We Finally Figured Out Why Eczema Is So Common and much, much more… - Which patients are the most affected by anxiety and depression after a melanoma diagnosis and what can we do about it? - Patients who are switched onto a biosimilar do “worse” than patients who start one as their first therapy – why? - We finally got eczema answers.  Turns out that air pollution, both indoor and outdoor, is the cause of the atopic dermatitis epidemic that started in the 1970s and is why eczema is more common in urban areas. - Ian Myles explains how he proved that air pollution is the driving force behind atopic dermatitis and helps our team understand what it all means  - Plus: Predictors of acne relapse after isotretinoin, dupilumab prevents cancer, how well does tralokinumab work in dupilumab "failures," ferulic acid for rosacea, cysteamine vs hydroquinone for melasma, and the best way to treat digital mucous cysts Guest: Ian A. Myles, MD, Mph Dr. Myles,  Principal Investigator, Epithelial Therapeutics Unit, graduated with a B.S. in biology from Colorado State University in 2001 and then obtained an M.D. from the University of Colorado in 2005. He completed an internal medicine residency at The Ohio State University prior to beginning fellowship training in allergy and clinical immunology at NIH. He worked under the mentorship of Dr. Sandip Datta investigating the mechanistic details of susceptibility to S. aureus skin infections. In 2011, Dr. Myles became a commissioned officer in the United States Public Health Service Commissioned Corps. LCDR Myles has supported several USPHS missions, from the Ebola virus vaccine trial in West Africa to congressional Gold Medal Ceremonies at the U.S. Capitol. In 2013, he was awarded a position as an assistant clinical investigator in the NIAID Transition Program in Clinical Research. Dr. Myles received his M.P.H. from George Washington University in 2016. In 2018, Dr. Myles became the head of the newly formed Epithelial Therapeutics Unit to evaluate the efficacy and safety of a topical, live bacterial treatment for atopic dermatitis (eczema). He is currently a participant in the Lasker Clinical Research Scholars and Distinguished Scholars programs.

    Not rated yet
  • PsA: The Derm Version

    · 46 min

    Psoriatic arthritis usually gets explained in a way that makes derms want to leave the room. Not this episode. Drs. Zirwas, Ferris, and Patton are joined by double-boarded rheum-derm expert Dr. Saakshi Khattri for a practical, entertaining deep dive into recognizing PsA and making smarter treatment decisions — without the rheumatology overload.

    Not rated yet
  • Sunscreen Heresy & Other Hot Takes

    · 47 min

    This week’s Derms on Drugs is a classic six-pack episode. From cutting-edge CTCL therapies to biologic safety data and the growing world of oral photoprotection, the group covers the studies worth knowing—plus a few opinions spicy enough to start a conference hallway argument.

    Not rated yet
  • Steroids, Estrogen & Other Bad Decisions

    · 56 min

    This week on Derms on Drugs, the gang goes deep into vulvar dermatology with double-boarded derm/OB-GYN expert Dr. Kelly Tyler. From lichen sclerosus and recurrent candidiasis to estrogen, lasers, PRP, and the wildly overmarketed “Mona Lisa” treatments, they they break down what helps, what doesn’t, and what’s probably paying for someone’s boat. Equal parts practical pearls and inappropriate laughter — exactly how medical education should be.

    Not rated yet
  • Pick Your Own Treatment Adventure

    · 38 min

    This week’s Derms on Drugs is a 6-pack that covers a little bit of everything and somehow lands on: just do what you want. From a randomized trial showing eczema doesn’t care how often you shower to wild dupilumab data—plus a heating pad “treatment” that might actually work and a new JAK/TYK2 raising eyebrows—this one is equal parts useful, questionable, and predictably unpredictable.

    Not rated yet
  • Regenerative Derm: Baloney or Breakthrough?

    · 56 min

    Feeling a little worn down by Friday? A bit… degenerated, perhaps? This week’s Derms on Drugs goes off the beaten path and into the world of regenerative dermatology, where the line between legit science and “sounds like a scam” gets… blurry. With guest Dr. Amanda Hill, the team tackles hormones, skin aging, and whether we’re actually regenerating tissue—or just getting better at marketing it. From estrogen myths (and what we got very wrong) to PRP, exosomes, and the truth about “bioidentical” everything, this one separates hype from what might actually matter—and calls out a lot of nonsense along the way.

    Not rated yet
  • When the Data Get Personal

    · 57 min

    This week’s Derms on Drugs 6-pack moves past theory and into real decisions—what actually helps you pick the rightdrug for the patient in front of you. From gene expression profiling that predicts JAK vs Th2 response to the growing concern around dupilumab and CTCL, and more, this episode separates signal from noise—and gives you a few things you won’t forget (looking at you, abscopal effect).

    Not rated yet
  • Derms on Drugs takes on the AAD late breaking research, Part 2

    · 54 min

    Couldn’t make it to Denver for AAD—or made it to Part 1 but still hungry for the rest? Derms on Drugs is back with Part 2, finishing the job with more of the hottest late-breaking data in dermatology. Join Drs. Zirwas, Ferris, and Patton as they dive into the remaining abstracts, breaking down what actually matters (and what doesn’t) with the same unfiltered, practical take you expect from the DoD crew.

    Not rated yet
  • Derms on Drugs takes on the AAD late breaking research, Part 1

    · 51 min

    Couldn't make it to Denver for the AAD conference? Made it to Denver but maybe had one too many Old Fashions to make it to the late breaking abstract presentations? DoD may have had too many Old Fashions (it was really only Dr. Zirwas), but we still made it to the session with all the hottest data in the world of dermatology. Join Drs. Zirwas, Ferris, and Patton for the first episode of this pair that'll keep you ahead of the curve.

    Not rated yet
  • What Actually Changes Practice (and What Doesn’t)

    · 54 min

    Some studies make you rethink everything. Others… not so much. This week, it’s a classic Derms on Drugs 6-pack that sorts through what’s actually useful, what’s overhyped, and what might quietly change how you practice. Can Castle testing spare sentinel node biopsies—or not yet? And why U.S. derms (and Patton) disagree with Europe on BP guidance. Plus more!

    Not rated yet